Literature DB >> 3669495

Serum apolipoprotein profile of patients with chronic renal failure.

P O Attman1, P Alaupovic, A Gustafson.   

Abstract

Serum concentrations of apolipoproteins A-I, A-II, B, C-I, C-II, C-III and E were determined by electroimmunoassay in 56 patients with chronic renal failure (CRF) in the predialytic phase. The results were compared with those obtained in asymptomatic normolipidemic subjects, patients with type IV hyperlipoproteinemia, and patients with type II diabetes mellitus. CRF patients had reduced concentrations of ApoA-I and ApoA-II, normal levels of ApoB and ApoC-I, and increased concentrations of ApoC-II and, in particular, of ApoC-III. There was a significant reduction in the levels of ApoE, especially in male patients. In comparison with type IV, hyperlipoproteinemic patients, CRF patients had lower concentrations of ApoA-I, ApoA-II, ApoB, ApoC-I and, particularly, ApoE; there was no difference in ApoC-III levels reflecting the hypertriglyceridemia common to both disorders. Similar but less marked differences were also found in comparison with type II diabetics. The findings suggest that in CRF, the accumulation of ApoC-III-enriched lipoprotein particles accompanied by a moderate hypertriglyceridemia may be caused more probably by an impaired catabolism than overproduction of triglyceride-rich lipoproteins. CRF patients with vascular disease tended to have higher serum concentrations of triglycerides, cholesterol and ApoB and lower ApoA-I/ApoC-III and ApoA-I/ApoB ratios than patients without vascular disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3669495     DOI: 10.1038/ki.1987.219

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

1.  Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.

Authors:  N S Shachter; T Ebara; R Ramakrishnan; G Steiner; J L Breslow; H N Ginsberg; J D Smith
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.

Authors:  Mikael Larsson; Evelina Vorrsjö; Philippa Talmud; Aivar Lookene; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

3.  Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D.

Authors:  Arpita Basu; Ionut Bebu; Alicia J Jenkins; Julie A Stoner; Ying Zhang; Richard L Klein; Maria F Lopes-Virella; W Timothy Garvey; Matthew J Budoff; Petar Alaupovic; Timothy J Lyons
Journal:  J Lipid Res       Date:  2019-06-15       Impact factor: 5.922

4.  Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort.

Authors:  Alicia J Jenkins; Jeremy Yu; Petar Alaupovic; Arpita Basu; Richard L Klein; Maria Lopes-Virella; Nathaniel L Baker; Kelly J Hunt; Daniel T Lackland; W Timothy Garvey; Timothy J Lyons
Journal:  J Diabetes Complications       Date:  2013-07-11       Impact factor: 2.852

5.  The effect of metabolic acidosis on serum apolipoprotein A I and apolipoprotein B levels in children with chronic renal failure.

Authors:  Z Bircan; A Kaplan; M Soran; M Söker; M Kervancioğlu; A Sahin; M Kilinc
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

Review 6.  [Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].

Authors:  C J Olbricht
Journal:  Klin Wochenschr       Date:  1991-08-01

7.  Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production.

Authors:  Hamid Moradi; Hamid M Said; Nosratola D Vaziri
Journal:  Transl Res       Date:  2012-12-03       Impact factor: 7.012

Review 8.  Cholesterol Metabolism in CKD.

Authors:  Allison B Reiss; Iryna Voloshyna; Joshua De Leon; Nobuyuki Miyawaki; Joseph Mattana
Journal:  Am J Kidney Dis       Date:  2015-09-01       Impact factor: 8.860

9.  In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide.

Authors:  Nosratola D Vaziri; Hamid Moradi; Madeleine V Pahl; Alan M Fogelman; Mohamad Navab
Journal:  Kidney Int       Date:  2009-05-27       Impact factor: 10.612

10.  Survival and predictors of death in dialysed diabetic patients.

Authors:  M Koch; B Thomas; W Tschöpe; E Ritz
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.